Get started
Work

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Year: 2025
Type: review
Abstract: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.
DOI: 10.3322/caac.21870
Authors: Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, Zeynep Irem Ozay, Arshit Narang, Tony Crispino, Talia Golan, Jennifer K. Litton, Umang Swami, Kathleen N. Moore, Neeraj Agarwal
Institutions: University of Utah, Huntsman Cancer Institute, The University of Texas Southwestern Medical Center, Sheba Medical Center, The University of Texas MD Anderson Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,330
OpenAlex ID: W4406247210
FWCI: 2.804
Cites: 110
Cited by: 24
Related to: 10